Climb Bio (CLYM) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- −$0.13
- EPS estimate
- −$0.19
- EPS surprise
- +29.73%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Aug 12, 2025
Climb Bio reported Q2 2025 results on August 12, 2025. It posted a loss of $0.13 per share, narrower than the expected loss of $0.19, a beat of 29.73%. No revenue was reported and no revenue estimate was given. A year earlier, in Q2 2024, the loss was $1.81 per share, with no estimate given for that quarter.
The record is short and has a gap. The table holds 13 quarters, with no rows between Q1 2023 and Q2 2024. Every quarter shown is a loss. The only full year in the table is 2022, at a loss of $1.72 per share. The largest quarterly loss was $3.11 in Q2 2021, the first row, followed by $1.81 in Q2 2024. Since then, losses have stayed at $0.13 per share in three of four quarters, with $0.31 in Q1 2025. Of the 11 quarters that had an estimate, Climb Bio beat seven and missed four.
The table has no report after August 2025. In the years shown, Climb Bio reported Q3 between November 8 and November 14. A newer report would show whether quarterly losses stayed near the $0.13 per share level of recent quarters.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Aug 12, 2025 | −$0.19 | −$0.13 | +29.73% | $0.00 | SEC |
| Q1 2025 | May 14, 2025 | −$0.15 | −$0.31 | −106.67% | $0.00 | SEC |
| Q4 2024 | Mar 25, 2025 | −$0.15 | −$0.13 | +13.33% | $0.00 | SEC |
| Q3 2024 | Nov 12, 2024 | $0.00 | −$0.13 | +0.00% | $0.00 | SEC |
| Q2 2024 | Aug 14, 2024 | $0.00 | −$1.81 | +0.00% | $0.00 | SEC |
| Q1 2023 | May 11, 2023 | −$0.25 | −$0.84 | −236.00% | $0.00 | SEC |
| Q4 2022 | Mar 6, 2023 | −$0.38 | −$0.29 | +23.68% | $0.00 | SEC |
| Q3 2022 | Nov 14, 2022 | −$0.43 | −$0.37 | +14.45% | $0.00 | SEC |
| Q2 2022 | Aug 15, 2022 | −$0.47 | −$0.56 | −19.99% | $0.00 | SEC |
| Q1 2022 | May 16, 2022 | −$0.56 | −$0.50 | +11.24% | $0.00 | SEC |
| Q4 2021 | Mar 7, 2022 | −$0.63 | −$0.40 | +36.51% | $0.00 | SEC |
| Q3 2021 | Nov 8, 2021 | −$0.89 | −$0.70 | +21.10% | $0.00 | SEC |
| Q2 2021 | Sep 13, 2021 | −$2.38 | −$3.11 | −30.95% | $0.00 | — |
Quarterly revenue
Frequently asked questions
When did Climb Bio (CLYM) last report earnings?
Climb Bio last reported on Aug 12, 2025, covering fiscal Q2 2025.
Did CLYM beat earnings estimates?
Yes. Climb Bio reported EPS of −$0.13 for Q2 2025 against a −$0.19 estimate — a 29.73% beat.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.